EDAILY - JANSSEN
App combined with smartwatch enables collection of longitudinal patient RWE data for evidence-based outcomes
An innovative digital health solution with smartwatch integration supporting psoriatic arthritis patients in pan-European clinical trial
The challenge
Psoriatic arthritis (PsA) symptoms like morning stiffness and fatigue can be draining. But the subjective and diverse experiences of people who have PsA make it a difficult condition to study in traditional clinical trials. To develop effective treatments, clinical research needs to be more directly informed by patient experience. There is a need to go beyond conventional clinical trial measurements to better understand the impact psoriatic arthritis has on people’s daily lives. The collection and utilization of Patient Reported Outcomes (PROs) is expected to enable the transition towards more holistic care, aiming to achieve a higher quality of life for patients.
The innovation
Studies have shown that PROs deliver better ecological validity when filled by patients outside the clinic. Here, digital health tools are the obvious choice. The eDaily solution builds upon that, by collecting weekly digital patient questionnaires, patient-reported outcomes (PROs), and other health-related quality-of-life indicators to keep participants motivated and engaged. eDaily uses a smartwatch integrated app to collect longitudinal patient data and digital biomarkers for calories, movement and sleep. With this solution, Janssen found a unique way to engage patients and capture valuable data on the impact of PsA on sleep, activity levels and disease relevant symptoms.
The outcome
By leveraging the power of digital health services and co-created with people living with PsA, Janssen has built a more patient-centric approach to clinical trials. This research into PsA is yielding more inclusive and holistic insight into how the disease affects PsA patients, enabling Janssen to be even more patient-centric and inform its approach to the market. This is a win-win for all: Users of the digital health service benefit from highly relevant personal suggestions for managing their PsA, while Janssen benefits from robust evidence-based R&D and unique market differentiation.